Results 41 to 50 of about 50,656 (201)

Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]

, 2010
Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Shyangdan, D. (Deepson), Royle, Pamela, Clar, C., Sharma, Pawana, Waugh, Norman   +4 more
core   +4 more sources

Effects of Treatment with Glucagon-like Peptide-1 Receptor Analogues on the Diabetic Foot

Biomedicines
Background/Objectives: Diabetic foot disease is one of the most severe and disabling complications of type 2 diabetes mellitus, resulting from the interaction between peripheral neuropathy, peripheral arterial disease, and infection.
Mercedes Ortiz Romero, David Rodríguez de Vera Gómez, Pablo Rodríguez de Vera Gómez, Luis María Gordillo Fernández   +3 more
doaj   +1 more source

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

Molecular Metabolism, 2021
Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes and obesity. They elicit robust improvements in glycemic control and weight loss, combined with cardioprotection in individuals at risk of or with pre ...
Laurie L. Baggio, Daniel J. Drucker
doaj   +1 more source

Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents [PDF]

, 2017
peer-reviewedThe gut hormone glucagon-like peptide (GLP)-1 and its analogues represent a new generation of anti-diabetic drugs, which have also demonstrated propensity to modulate host lipid metabolism.
Cryan, John F., Dinan, Timothy G., Kent, Robert M., Mandal, Rupasri, Murphy, Kiera, O’Connor, Paula M., Patterson, Elaine, Peterson, Veronica L., Ross, R Paul, Ryan, Paul M, Seeley, Randy J., Stack, Helena, STANTON, CATHERINE, Wishart, David S.   +13 more
core   +5 more sources

Unraveling the obesity–asthma link: A new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease

Journal of International Medical Research
The global prevalence of obesity and asthma has escalated in parallel over recent decades, presenting an intertwined public health crisis. Obesity not only increases the risk of asthma development but also complicates its clinical course by altering ...
Francesco Menzella, Marcello Cottini, Rory Chan   +2 more
doaj   +1 more source

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics

European Psychiatry, 2021
Introduction Glucagon-like peptide-1 (GLP-1) is an endogenous peptide that stimulates insulin secretion and decreases glucagon secretion. The use of GLP-1 receptor agonists (GLP-1RA) showed efficacy reducing the weight and glucose levels in patients ...
A. Delgado, J. Velosa, R. Avelar, J. Franco, M. Heitor   +4 more
doaj   +1 more source

Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro [PDF]

, 2003
The growth rate of numerous cancer cell lines is regulated in part by actions of neuropeptides of the vasoactive intestinal peptide (VIP) family, which also includes pituitary adenylate cyclase-activating peptide (PACAP), glucagon, and peptide histidine ...
Alleaume, Céline, Dufès, Christine, Montoni, Alicia, Muller, Jean-Marc, Olivier, Jean-Christophe   +4 more
core   +1 more source

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Molecular Metabolism, 2022
Objective: Pharmacological strategies that engage multiple mechanisms-of-action have demonstrated synergistic benefits for metabolic disease in preclinical models.
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, Bhavesh Premdjee, Karina Rahr Hjøllund, Yantao He, Ann Maria Kruse Hansen, Anette K. Olsen, Diego Perez-Tilve, Richard D. DiMarchi, Brian Finan   +10 more
doaj   +1 more source

The extrapancreatic effects of glucagon-like peptide-1 and related peptides [PDF]

, 2009
Context: Glucagon-like peptide-1 (GLP-1) 7-36 amide, an insulinotropic hormone released from the intestinal L cells in response to nutrient ingestion, has been extensively reviewed with respect to -cell function.
Abu Hamdah, Rania, Rabiee, Atoosa, Meneilly, Graydon S., Shannon, Richard P., Andersen, Dana K., Elahi, Dariush   +5 more
core   +1 more source

Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. [PDF]

, 2018
Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide ligands of these receptors display biased agonism and this may provide future therapeutic advantage.
Andreassen, Arthur Christopoulos, Baldwin, Barwell, Belcheva, Berendsen, Black, Booe, Caroline A. Hick, Christopher A. Reynolds, Christopoulos, Christopoulos, Cosman, Dal Maso, de Graaf, Debbie L. Hay, Dehua Yang, Denise Wootten, Doerr, Dolinsky, Dong, Dong, Emma Dal Maso, Epand, Essmann, Eswar, Feyen, Furness, Gingell, Giuseppe Deganutti, Hamelryck, Harikumar, Harvey, Hay, Hilton, Huang, Humphrey, Johansson, Jorgensen, Koole, Koole, Krautler, Kuestner, Kuwasako, Kuwasako, Langston, Li, Liang, Lomize, Loncharich, Ming-Wei Wang, Minhas, Morfis, Orlowski, Patrick M. Sexton, Poyner, Sebastian G.B. Furness, Sommer, Udawela, Udawela, Vi Pham, Watkins, Weaver, Weston, Weston, Woolley, Woolley, Wootten, Wootten, Yue Zhu, Zhang   +70 more
core   +1 more source